

Brieuc Sautois MD., PhD



Brieuc Sautois MD., PhD

PROFESSOR

Urinary Tract Cancer Specialist

Head and professor of clinics at the department of oncology University Hospital Center (CHU) of Liège, researcher of clinical trials of phase I-III. He is currently involved in the daily clinical management of patients with solid tumors with interest in those of the urinary tract and head and neck. He has more than 40 international scientific publications as author and co-author.

Full name: Brieuc Sautois

Country: Belgium

Current Position:

2006-present Head of clinics. Department of medical oncology. CHU of Liège. Belgium.

Education:

2016 Good Clinical Practice-International Council for the Harmonization of Technical Requirements, Pharmaceutical Products for Human Use in Professionals (GCP-ICH) training for clinical research professionals: workshops completion, December 23, 2010, November 22, 2012, November 13, 2014, and October 14, 2016.

2009 European certification of 5 years in medical oncology (Passed the ESMO exam).

2008 Certification of the board in medical oncology. Belgium.

2002 PhD. University of Liège (ULg). Belgium.

1999 Specialist in internal medicine and medical oncology. ULg. Belgium.

1992 Doctor in medicine. ULg. Belgium.

1988 Degree in medicine. The University of Mons-Hainaut. Belgium.

Experience:

2006-present Head of clinics. Department of medical oncology. CHU of Liège. Belgium.

2002-2006 Deputy head of clinics. Department of medical oncology. CHU of Liège. Belgium.

Scientific publications

Number of publications as author or co-author: 46

Clinical Trials: 14 (Cancer of the urinary tract, head and neck)

Recent scientific publications:

Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC). Seront E, Rottey S, Filleul B, Glorieux P, Goemine JC, Verschaeve V, Vandebulcke JM, Sautois B, Boegner P, Gillain A, van Maanen A, Machiels JP. *BJU Int*, 2016, Jan 18, doi: 10.1111/bju.13415. [Epub ahead of print].

Weekly cisplatin with radiotherapy for head and neck cancer: a single center retrospective experience. Sautois B, Schroeder H, Martin M, Piret P, Demez P, Bouchain O, Mutijima E, Moreau P. *JBUON*, 2016, 21, 4, 979-88.

Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy. Machiels JP, Van Maanen, Vandebulcke JM, Filleul B, Seront E, Henry S, D'Hondt L, Lonchay C, Holbrechts S, Boegner P, Brohée D, Dequanter D, Louviaux, Sautois B, Whenham N, Berchem G, Vanderschueren B, Fontaine C, Schmitz S, Gillain A, Schoonjans J, Rottey S: *The Oncologist*, 2016, 21, 1-10.